Spring Sale: Up to 50% OFF · Ends Tonight

Does Mounjaro Cause Hair Loss? The Tirzepatide Data

Updated 2026-04-17 9 min read By Provant Labs Research Team

Yes, Mounjaro causes hair loss. The SURMOUNT-1 Phase 3 trial (n=2,539) found alopecia in 4.9-5.3% of tirzepatide patients versus 0.9% of placebo patients. The Zepbound FDA label, which uses the same drug at the obesity dose, reports 7.1% in women versus 0.5% in men. The sex gap is real, it's large, and it's consistent across every data source.

Here's the complete breakdown of what the clinical trials actually found.

What Tirzepatide Is (and Why Mounjaro and Zepbound Data Are Interchangeable)

Tirzepatide is a dual GIP/GLP-1 receptor agonist. It targets two gut hormone receptors simultaneously, which is what distinguishes it from semaglutide (which only targets GLP-1 receptors). The molecule is identical whether it's branded as Mounjaro (the diabetes indication) or Zepbound (the obesity indication).

The clinical trials that generated the most detailed hair loss data used Zepbound doses (the obesity indication, which produces greater weight loss). When you see Zepbound data on alopecia, that's tirzepatide hair loss data. It applies to Mounjaro patients who are losing significant weight.

SURMOUNT-1: The Largest Tirzepatide Trial

SURMOUNT-1 (Jastreboff et al., NEJM 2022) was a Phase 3 randomized controlled trial testing tirzepatide vs placebo for obesity treatment. It's the single most important data source for tirzepatide hair loss.

Trial parameters:

Alopecia results:

Dose Alopecia cases Rate
5mg 32 cases 5.1%
10mg 34 cases 5.3%
15mg 31 cases 4.9%
Placebo 6 cases 0.9%

The rate doesn't climb with dose in the way you might expect. The 5mg arm produced alopecia at nearly the same rate as 15mg. This suggests the threshold effect: once you're losing significant weight, the hair loss risk is already engaged. Losing more weight doesn't proportionally increase the risk.

Weight loss in SURMOUNT-1: -15% body weight (5mg) to -20.9% (15mg) versus -3.1% placebo. The placebo group's 0.9% rate, in patients losing only 3% of body weight, gives you the background signal from the trial population itself.

SURMOUNT-3: 7.0% in the Intensive Arm

SURMOUNT-3 (Wadden et al., Nature Medicine 2023) tested tirzepatide in patients who had already lost weight through an intensive behavioral intervention, then continued losing with the drug.

Alopecia:

The 7.0% figure from SURMOUNT-3 is the highest published alopecia rate from any tirzepatide trial. Participants in this trial had already undergone intensive weight loss before adding tirzepatide, meaning total cumulative weight loss was substantial. That context likely explains the elevated rate.

The Meta-Analysis: OR 5.76

A pooled meta-analysis of the SURMOUNT trials (PMC11576767) calculated the overall odds ratio for alopecia with tirzepatide versus placebo.

Tirzepatide alopecia OR: 5.76 (95% CI: 2.95-11.23)

An odds ratio of 5.76 means tirzepatide-treated patients were nearly 6 times more likely to report alopecia than placebo patients across these trials. The confidence interval (2.95-11.23) is wide but entirely above 1.0. This is a robust statistical signal.

For context: an OR above 2.0 is typically considered clinically meaningful in pharmacological safety research. 5.76 is substantial.

The Zepbound Label Sex Data: 7.1% vs 0.5%

The Zepbound FDA label (pooled Studies 1 and 2) provides the most detailed sex-stratified breakdown of any GLP-1 medication's prescribing information.

Group Tirzepatide Placebo
Women 7.1% 1.3%
Men 0.5% 0.0%
Combined ~5% ~1%

Women on tirzepatide experienced alopecia at 14x the rate of men on the same drug. The women's placebo rate (1.3%) versus men's placebo rate (0.0%) suggests women in these trials had some baseline hair loss vulnerability, but the drug amplified that difference enormously.

And the label notes: no patient discontinued tirzepatide treatment because of alopecia. Hair loss was real and documented, but not severe enough at the population level to drive treatment discontinuation in the formal trial data.

Why Women Are Disproportionately Affected

The 14x sex differential in Zepbound data isn't random. Three mechanisms explain it.

Hormonal sensitivity. Tirzepatide, like all GLP-1 medications, reduces LH (luteinizing hormone) and FSH (follicle-stimulating hormone) as a secondary effect of weight loss and metabolic change. Lower LH/FSH means lower estrogen production. This mimics the hormonal shift after childbirth, when estrogen drops sharply and triggers diffuse shedding in women who wouldn't otherwise be losing hair. Men don't experience this estrogen-mediated pathway.

Hair follicle biology. Women's follicles are more sensitive to systemic stress signals. During telogen effluvium (the clinical mechanism behind GLP-1 hair loss), the follicle decides whether to stay in the active growth phase (anagen) or shift to rest (telogen). In women, hormonal change is a potent signal to shift. The body interprets caloric restriction and hormonal change as a stress state, and the follicle responds accordingly.

Cumulative weight loss. Women seeking obesity treatment on Mounjaro often start the medication with higher relative body weight percentages, and the medication's weight loss in women in these trials was proportionally significant. The Annals of Dermatology 2024 retrospective study (n=140, 78.6% women) found the average weight loss rate associated with TE was 3.54 kg per month. Tirzepatide frequently exceeds that rate, especially in the first few months.

Pharmacovigilance: Godfrey et al. 2025

Beyond the controlled trials, pharmacovigilance data from real-world adverse event reporting adds another layer of evidence.

Godfrey et al. 2025 (JEAVD) analyzed FDA Adverse Event Reporting System (FAERS) data from 2022-2023, specifically for alopecia reports linked to GLP-1 medications.

An ROR above 1.0 indicates a drug-event combination is reported more often than expected given the full FAERS database. Both tirzepatide (1.73) and semaglutide (2.46) exceed this threshold. The consumer-driven nature (84%) of these reports reflects a side effect patients notice and report directly, often before it surfaces in structured medical documentation.

The semaglutide ROR (2.46) is higher than tirzepatide's (1.73). This could reflect the earlier market entry of semaglutide, generating more total reports, or a genuine pharmacological difference. Without a head-to-head trial, the comparison is directional at best.

The TriNetX Real-World Cohort

The TriNetX multicenter study used data from 67 healthcare organizations and matched 547,993 GLP-1 users against 547,993 non-users with similar baseline characteristics.

At 12 months, GLP-1 users showed elevated odds across three hair loss diagnoses:

This is the largest real-world dataset on GLP-1 hair loss effects. The androgenic alopecia finding deserves attention: unlike telogen effluvium (which is temporary), androgenic alopecia is a progressive condition driven by DHT sensitivity in genetically predisposed follicles. A 1.64 odds ratio suggests GLP-1 treatment either uncovers or accelerates an underlying genetic pattern in some patients.

How Mounjaro Hair Loss Compares to Wegovy Hair Loss

Patients often ask whether Mounjaro or Wegovy causes more hair loss. The honest answer is: comparable, not clearly different.

The SURMOUNT-1 rate (4.9-5.3%) versus the Wegovy injectable label rate (3%) might suggest tirzepatide is worse. But the OASIS 1 trial for oral semaglutide found 6.9%. And both produce greater hair loss at higher weight loss amounts, so the comparison depends heavily on how much weight each patient loses.

The Godfrey 2025 pharmacovigilance data shows semaglutide with a higher ROR (2.46) than tirzepatide (1.73), which is the opposite of what the trial percentages suggest.

No head-to-head trial exists. The Zepbound label's 7.1% in women is the highest sex-specific figure published for any GLP-1 medication, but that's from the obesity indication. The evidence doesn't clearly rank one drug above the other for hair loss risk.

The Mechanism in Brief

Mounjaro triggers hair loss through the same pathway as all GLP-1 medications: telogen effluvium from rapid weight loss, with hormonal shifts as a secondary contributor.

During rapid caloric restriction, the hair follicle matrix (the highest cell-division tissue in the body) receives metabolic stress signals. Large numbers of follicles shift from active growth (anagen) into resting phase (telogen). Two to four months later, those resting follicles release their club hairs simultaneously. This is why hair loss starts months after you begin the medication, not immediately.

And because you're still actively losing weight on Mounjaro, the trigger doesn't stop. The shedding can persist for as long as you're in rapid weight loss. Recovery begins when weight stabilizes and nutritional status recovers.

Ferritin below 30 ng/mL is strongly associated with prolonged hair loss. Zinc depletion, common with caloric restriction, is a contributing factor. These are addressable.

What the Data Supports Doing

The evidence supports active intervention rather than waiting it out.

Topical ingredients with published clinical evidence can work on the follicle environment while you remain on Mounjaro. Rosemary extract matched minoxidil 2% in a head-to-head RCT (Panahi et al., SKINmed 2015, n=100), and Patel et al. 2025 (Cureus, n=90) found rosemary-lavender produced a 57.73% improvement in growth rate and 68.70% improvement in thickness. Saw palmetto reduced shedding 22.19% and increased density 7.61% in an RCT (Sudeep et al., CCID 2023, n=80). Bioactive peptides addressing the follicle environment have additional evidence from smaller trials.

The GLP-1 hair loss guide covers the full mechanism and timeline. The is GLP-1 hair loss permanent? article addresses the recovery question in detail. For a topical option targeting the scalp directly, the PD-5 Complex combines these ingredients in a formula designed for this specific pattern.

FAQ

Does Mounjaro cause hair loss at every dose?

The SURMOUNT-1 data shows similar rates across 5mg (5.1%), 10mg (5.3%), and 15mg (4.9%) doses, with a flat pattern rather than a dose-escalation pattern. Hair loss correlates more strongly with total weight lost than with the specific tirzepatide dose. Once you're losing significant weight, the risk appears engaged regardless of which dose you're on.

How long does Mounjaro hair loss last?

It typically persists as long as you're in rapid active weight loss. Once weight stabilizes, the shedding slows. The Annals of Dermatology 2024 retrospective cohort (n=140) found average recovery of 4.83 months after the trigger stabilized, without treatment. That range ran 0.5 to 16 months across individuals.

Is Mounjaro hair loss worse for women than men?

Yes, substantially. The Zepbound FDA label (same drug, obesity dose) reports 7.1% in women versus 0.5% in men. That's a 14-fold difference on the same drug. The Etminan 2025 real-world study on semaglutide found HR 2.08 for women (significant) and HR 0.86 for men (not significant). The mechanism involves GLP-1-mediated reduction in estrogen-related hormones, which hits women harder.

Why didn't my doctor mention this?

Mounjaro's prescribing information (the diabetes indication) doesn't list alopecia as prominently as the Zepbound obesity label. Prescribers focused on glycemic outcomes may not routinely discuss it. Verbatim from patient communities: "Nowhere in my extensive pre-Mounjaro research had anyone mentioned hair loss." The clinical trial data has been public since 2022, but prescriber communication lags significantly behind.

Does Mounjaro cause permanent hair loss?

For most people, no. Telogen effluvium from weight loss is temporary. The follicles aren't destroyed. But the TriNetX cohort study (n=547,993 matched pairs) found an elevated adjusted OR of 1.64 for androgenic alopecia, which is progressive. Some women may find that Mounjaro unmasks or accelerates an underlying genetic hair loss pattern. If your hair loss isn't diffuse (all-over thinning) but concentrated in specific areas, it's worth seeing a dermatologist to distinguish between TE and androgenic alopecia.

What's the difference between Mounjaro and Zepbound hair loss data?

Same molecule. Zepbound is tirzepatide for obesity. Mounjaro is tirzepatide for type 2 diabetes. The obesity indication produces greater weight loss, so the obesity trial data shows higher hair loss rates. If you're on Mounjaro and losing significant weight, the Zepbound trial data (including the 7.1% women's figure) is the most relevant reference point.

Ready to support your hair during your GLP-1 journey?

See the PD-5 Complex